Effects of Muscadine Grape Extract in Men With Prostate Cancer on Androgen Deprivation Therapy
Status:
Recruiting
Trial end date:
2022-04-01
Target enrollment:
Participant gender:
Summary
It is estimated that one-third of the more than 7 million deaths from cancer worldwide are
attributable to potentially modifiable risk factors, with 374,000 deaths preventable through
diet modification alone. Diet supplementation for the prevention or treatment of cancer is
attractive, as implementation is relatively easy, even in populations with reduced incomes
and resources. Grape extracts or active components isolated from grapes have received
attention as chemopreventive or therapeutic agents based upon their anti-proliferative,
anti-inflammatory, and anti-oxidant properties. Evidence from preclinical trials also
suggests that muscadine grape products may decrease systemic inflammation. This study builds
upon promising preclinical and clinical evidence to determine if the addition muscadine grape
extract (MGE) to androgen deprivation therapy (ADT) improves symptoms in men with prostate
cancer.